Eli Lilly and Co. has embarked on a significant expansion project in Kenosha County, Wisconsin, with plans to invest $3 billion in building a new facility in Pleasant Prairie. This expansion initiative is expected to create 750 permanent jobs in addition to 2,000 construction jobs. The state of Wisconsin has offered Eli Lilly and Co. $100 million in tax credits to support this expansion, making it the largest award granted under Wisconsin’s Enterprise Zone program.
The Wisconsin Economic Development Corp. (WEDC) will provide Eli Lilly and Co. with enterprise zone tax credits to facilitate the expansion project. These tax credits are contingent on the company meeting specific job creation and capital investment targets. Before the tax credits can be granted, Eli Lilly and Co. must achieve a goal of creating 200 jobs and investing $2.2 billion. Governor Tony Evers expressed his support for the project, highlighting the state’s designation as a U.S. Regional Tech Hub and its commitment to fostering innovation and economic growth.
Eli Lilly and Co.’s expansion aims to enhance its manufacturing capabilities to meet the increasing demand for injectable obesity and diabetes medications. The company’s investment in its Pleasant Prairie facility signifies a strategic move to bolster its manufacturing network and ensure the availability of life-changing treatments for patients worldwide. This expansion project aligns with Wisconsin’s efforts to position itself as a global leader in the field of biohealth and pharmaceuticals, supported by collaborations between the state, local officials, and key stakeholders.
The construction of the new facility in Pleasant Prairie will include a substantial addition comprising office and manufacturing space, warehouse facilities, and dock doors. Eli Lilly and Co. is targeting completion of the project by March 2026, with the support of various state, county, and local entities. The expansion project reflects not only the company’s commitment to advancing manufacturing capabilities but also its dedication to creating high-quality jobs and contributing to the economic vitality of the region. Additionally, Eli Lilly plans to enhance its manufacturing infrastructure worldwide, with a total investment of $23 billion since 2020.
In parallel with its expansion efforts, Eli Lilly and Co. is working closely with government agencies and local leaders to ensure the successful implementation of the project. The company’s collaboration with the WEDC and other stakeholders underscores a shared commitment to innovation, job creation, and community development. Furthermore, Eli Lilly’s investment in Wisconsin’s manufacturing sector is poised to have a substantial economic impact, generating employment opportunities and fostering technological advancements in the biohealth and pharmaceutical industries.
Key Takeaways:
– Eli Lilly and Co. is investing $3 billion in expanding its facility in Pleasant Prairie, Wisconsin, creating 750 permanent jobs and 2,000 construction jobs.
– The state of Wisconsin has granted the company $100 million in tax credits, the largest award under the state’s Enterprise Zone program.
– The expansion project is aligned with Wisconsin’s goal to become a global leader in biohealth and pharmaceuticals, supported by strategic partnerships with government agencies and local stakeholders.
– Eli Lilly and Co.’s commitment to innovation and economic growth is evident through its significant investments in manufacturing infrastructure, both locally and globally.
Read more on dailyreporter.com